No registrations found.
ID
Source
Brief title
Health condition
Atrial fibrillation
Antiarrhythmic drugs
AAD
Dormant conduction
Pulmonary Vein Isolation
PVI
Catheter ablation
Cryoballoon
Radiofrequent
Atriumfibrilleren
Boezemfibrilleren
Anti-aritmica
Sponsors and support
Intervention
Outcome measures
Primary outcome
Incidence of dormant conduction with adenosine challenge after initial successful PVI.
Secondary outcome
1. Incidence of AF during cessation of AAD drugs.
2. Recurrence of AF within 12 months of the procedure on ECG or >30 seconds on Holter/Vitaphone (With applied blanking period of 3 months)
Background summary
Antiarrhythmic medications are frequently stopped more than five half-lives before pulmonary vein isolation(PVI) with the idea that they can supress spontaneous firing and fractionation of the electrocardiograms that can be used to guide ablation. Therefore they might mask dormant conduction in pulmonary veins. However many institutions choose to continue antiarrhythmic drugs(AAD) periprocedural. As current guidelines don’t recommend continuation or cessation of AAD prior to pulmonary vein isolation we compare continuing antiarrythmic drugs prior to PVI to cessation of AAD’s in relation to the occurence of dormant conduction.
Study objective
As current guidelines don’t recommend continuation or cessation of AAD prior to pulmonary vein isolation we compare continuing antiarrythmic drugs prior to PVI to cessation of AAD’s in relation to the occurence of dormant conduction with adenosine after succesful PVI.
Study design
Acute and 12 months
Intervention
Continuation or discontinuation of antiarrhythmic drugs 5 half lives prior to PVI
T. Hesselink
Postbus 50 000
Enschede 7500 KA
The Netherlands
tel. (053) 487 2110
t.hesselink@mst.nl
T. Hesselink
Postbus 50 000
Enschede 7500 KA
The Netherlands
tel. (053) 487 2110
t.hesselink@mst.nl
Inclusion criteria
Adults with atrial fibrillation EHRA class II or higher during therapy with class I or III (excluding amiodaron) antiarrhythmic drugs eligible for PVI.
Exclusion criteria
-Usage of amiodaron (due to very long half life time(20-100 days) these patients will be excluded)
-Prior PVI or MAZE
- Asthmatic condition or contra indication for adenosine
-Participation in another study that is interfering with study practice
Design
Recruitment
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL5328 |
| NTR-old | NTR5437 |
| CCMO | NL54134.044.15 |
| OMON | NL-OMON42401 |